Iovance Biotherapeutics
(NASDAQ) IOVA
Iovance Biotherapeutics Financials at a Glance
Market Cap
$1.84B
Revenue (TTM)
$285.61M
Net Income (TTM)
$353.86M
EPS (TTM)
$-0.95
P/E Ratio
-4.33
Dividend
$0.00
Beta (Volatility)
1.41 (Average)
Dividend
$0.00
Beta (Volatility)
1.41 (Average)
Price
$4.12
Volume
733,252
Open
$3.69
Price
$4.12
Volume
733,252
Open
$3.69
Previous Close
$4.12
Daily Range
$3.69 - $4.20
52-Week Range
$1.66 - $5.63
Dividend
$0.00
Beta (Volatility)
1.41 (Average)
Price
$4.12
Volume
733,252
Open
$3.69
Previous Close
$4.12
Daily Range
$3.69 - $4.20
52-Week Range
$1.66 - $5.63
IOVA News
IOVA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Iovance Biotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
975
CEO
Frederick G. Vogt, PhD
Website
www.iovance.comHeadquarters
San Carlos, CA 94070, US
IOVA Financials
Key Financial Metrics (TTM)
Gross Margin
1%
Operating Margin
-1%
Net Income Margin
-1%
Return on Equity
-48%
Return on Capital
-46%
Return on Assets
-38%
Earnings Yield
-23.09%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.84B
Shares Outstanding
446.50M
Volume
733.25K
Avg. Volume
17.35M
Financials (TTM)
Gross Profit
$256.22M
Operating Income
$403.36M
EBITDA
$357.11M
Operating Cash Flow
$302.41M
Capital Expenditure
$33.84M
Free Cash Flow
$336.24M
Cash & ST Invst.
$296.98M
Total Debt
$48.44M
Iovance Biotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$71.43M
+44.8%
Gross Profit
$70.41M
+16985.1%
Gross Margin
98.57%
N/A
Market Cap
$1.84B
N/A
Market Cap/Employee
$2.19M
N/A
Employees
838
N/A
Net Income
$79.05M
+32.0%
EBITDA
$72.50M
+32.2%
Quarterly Fundamentals
Net Cash
$266.67M
-12.9%
Accounts Receivable
$81.76M
+15.3%
Inventory
$58.38M
-10.9%
Long Term Debt
$43.88M
-0.8%
Short Term Debt
$2.90M
-69.5%
Return on Assets
-38.23%
N/A
Return on Invested Capital
-45.61%
N/A
Free Cash Flow
$78.68M
+28.4%
Operating Cash Flow
$72.07M
+30.5%